leadf
logo-loader
viewBiocept Inc

Biocept awarded US patent to protect its Primer-Switch technology for the detection of rare cell mutations

The San Diego company’s technology detects rare cell mutations using circulating tumor DNA (ctDNA) analysis through real-time PCR

Biocept Inc - Biocept Inc wins US patent to protect its Primer-Switch technology for the detection of rare cell mutations
This is the second issued patent for the Primer-Switch technology as Biocept pursues worldwide patent protection

Biocept Inc (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests, said it has been awarded a US patent to protect its Primer-Switch technology. 

The San Diego company’s technology is useful for the detection of rare cell mutations using circulating tumor DNA (ctDNA) analysis through real-time PCR and associated analysis methods, including next-generation sequencing (NGS).

Biocept said the grant of the patent expands the company’s intellectual property protection for the detection of rare mutations, including cancer biomarkers found in tissue, blood and cerebrospinal fluid. This is the second issued patent for the Primer-Switch technology, and is another step as Biocept pursues worldwide patent protection.

READ: Biocept to provide coronavirus testing to mutli-state healthcare group

The company noted that its Primer-Switch technology provides another method for specifically enriching patient specimens for oncogene mutations of interest. Additionally, Primer-Switch technology can be used to enhance the performance and specificity of the PCR method, which is the most widely used amplification approach in diagnostic assays.

"Our Primer-Switch methodology has the potential to find rare mutations in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplification reactions are desired or required," Biocept CEO Michael Nall said in a statement. 

"This technology builds upon our ability to detect rare genetic events in addition to our Switch-Blocker technology, which we routinely use in our ctDNA Target Selector assays. This is another tool in our toolkit for methods to inform on biomarkers found in tissue, blood and cerebrospinal fluid to aid physician decision making in the treatment of their patients with cancer."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.43 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $59.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read